Quercetin as an antiviral agent against Coronavirus infection: Double blind clinical trial

Quercetin supplementation and covid 19 evolution: a randomized clinical trial in hospitalized patients

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

PACTR

Registry ID

PACTR202406512501178

Enrollment

244

Registered

2024-06-06

Start date

2021-05-01

Completion date

Unknown

Last updated

2026-09-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Respiratory

Interventions

treated group

untreated group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: male or female >20 years of age and SARS COV2 positif hospitalizes subjects

Exclusion criteria

Exclusion criteria: pregnant women or lactating and non hospitalized subjects

Design outcomes

Primary

Measure	Time frame
the reduction in complications and mortality releatedto the disease	—

Secondary

Measure	Time frame
the reduction in the duration of hospitalization	—

Countries

Tunisia

Contacts

Public Contactjihen jdidi

hospital university professor

jdiditrabelsijihen@glmail.com21651061561

Outcome results

None listed

Source: PACTR (via WHO ICTRP) · Data processed: Sep 19, 2026